The Department of Medical Oncology at Peking Union Medical College Hospital is a clinical key specialty construction project of the National Health and Family Planning Commission. It currently has 2 professors, 5 associate professors, 10 attending physicians, and 2 researchers. Among the 17 doctors, there are 12 PhDs and 5 Masters, forming a balanced talent team.
The department is currently dedicated to the diagnosis and comprehensive treatment of various solid tumors, including breast cancer, lung cancer, lymphoma, gastrointestinal (esophagus, stomach, colorectal, pancreas, liver and bile duct) tumors, urogenital (kidney, ureter, bladder, prostate) tumors, neuroendocrine tumors, head and neck tumors, soft tissue tumors, thyroid cancer, and melanoma, offering chemotherapy, hyperthermic intraperitoneal chemotherapy, molecular targeted therapy, and immunotherapy. It has accumulated unique experience in treating complex and difficult cases such as rare tumors, geriatric tumors, and tumors with comorbidities. The department organizes and participates in multidisciplinary collaborative groups (MDT) for pancreatic, gastrointestinal, thoracic, intracranial germ cell, head and neck, and urological tumors. The annual outpatient volume is 32,000 visits, with over 5,000 inpatient admissions. The department also undertakes national and municipal medical tasks such as high-ranking health care and support for border areas.
The Department of Medical Oncology is a pioneer in advocating the concept of 'standardized cancer treatment' in China, adhering to advanced treatment philosophies such as 'personalized treatment,' 'multidisciplinary collaboration,' and 'precision cancer therapy' in clinical practice. The department has a strong academic atmosphere, holding weekly discussions on new and difficult cases, and annually organizing national continuing education courses and neuroendocrine tumor workshops. It participates in international oncology academic conferences such as ASCO, ESMO, and JSMO to stay updated on the latest advancements in cancer treatment. The department is staffed with highly qualified personnel, most of whom have overseas study experience, and has established academic connections with world-class cancer research institutions such as MD Anderson, NYP, UCLA, UCSF, the Cancer Institute Hospital of Japanese Foundation for Cancer Research, and the National Cancer Center Japan, inviting internationally renowned scholars for exchanges annually.
The department currently has 1 doctoral supervisor and 2 master's supervisors, training 2-3 graduate students annually. It has a tumor basic research laboratory and collaborates with the National Key Laboratory of Molecular Biology of the Chinese Academy of Medical Sciences to conduct research in cell biology, molecular biology, and tumor immunology. It is currently a 'National Clinical Trial Base for Cancer Drugs,' conducting an average of over 20 I-IV phase clinical trials annually. The department has undertaken or participated in multiple national and ministerial research projects such as the '11th Five-Year Plan,' '863 Program,' and the National Natural Science Foundation. It also provides education for undergraduate and graduate students from Peking Union Medical College and conducts ongoing training for physicians. The department's ward has been recognized as a 'Beijing Demonstration Ward for Cancer Pain' and also undertakes national and municipal training tasks for oncology nursing.
The Department of Medical Oncology will continue to uphold the spirit of 'rigor, precision, diligence, and dedication' of Peking Union Medical College, wholeheartedly providing high-quality medical services for cancer patients!
Century-Old Heritage · Premier Specialties
The Department of Medical Oncology at Peking Union Medical College Hospital is a national clinical key specialty integrating medical care, education, and research. Led by renowned oncology experts, it has a profound foundation in chemotherapy, molecular targeted therapy, immune checkpoint inhibitors, antibody-drug conjugates (ADC), and clinical trial research (GCP) for gastrointestinal tumors, lung cancer, breast cancer, urological tumors, neuroendocrine tumors, and malignant melanoma.
Based on next-generation sequencing molecular profiling, we tailor combined treatment plans covering targeted therapy, immunotherapy, chemotherapy, and anti-angiogenesis for each cancer patient, emphasizing dual benefits of quality of life and survival.
First-line targeted therapy based on precise genetic mutation testing (EGFR/ALK/ROS1/KRAS/BRAF, etc.)
PD-1/PD-L1/CTLA-4 immune checkpoint inhibitors combined with dual antibodies and anti-angiogenic drug regimens
Novel antibody-drug conjugates (ADC) for targeted delivery of precise anti-tumor treatment
Neoadjuvant conversion therapy for early and locally advanced malignant tumors and postoperative adjuvant maintenance therapy
International and domestic innovative anti-cancer drug I-III phase clinical studies as a National Drug Clinical Trial Institution (GCP)
Chief Physician, Professor, Doctoral Supervisor
Core Indications & Conditions Treated
Specialist in interventional pain medicine, ultrasound/CT-guided radiofrequency ablation for trigeminal and postherpetic neuralgia, and intrathecal drug pumps for refractory cancer pain.
Chief Physician, Professor, Doctoral Supervisor
Core Indications & Conditions Treated
Director of Pulmonary and Critical Care Medicine at PUMCH, national authority in lung cancer targeted therapy, immuno-oncology, and interventional bronchoscopy.
Chief Physician, Professor, Doctoral Supervisor
Core Indications & Conditions Treated
Vice President of the Chinese Society of Hematology. Leading master in autologous stem cell transplantation, multiple myeloma, and lymphoma targeted therapies.
Chief Physician, Professor, Doctoral Supervisor
Core Indications & Conditions Treated
Director of Hematology at PUMCH and internationally renowned authority on POEMS syndrome and systemic AL amyloidosis, authoring definitive global clinical criteria.
Chief Physician, Professor, Doctoral Supervisor
Core Indications & Conditions Treated
Director of Traditional Chinese and Integrative Medicine at PUMCH, expert in integrative care for diabetic neuropathy, supportive oncology, and herbal immunomodulation.
Associate Chief Physician, Associate Professor
Core Indications & Conditions Treated
Dr. Guan Mei is an Associate Chief Physician and Associate Professor in Medical Oncology, specializing in chemotherapy and targeted therapy for liver and abdominal metastatic tumors.
Associate Chief Physician
Core Indications & Conditions Treated
Dr. Li Xiaoyuan is an Associate Chief Physician specializing in various solid tumors, including lung and gastrointestinal cancers.
Associate Chief Physician, Associate Professor
Core Indications & Conditions Treated
Dr. Zhou Jianfeng is an Associate Chief Physician and Associate Professor in Medical Oncology, specializing in the comprehensive and personalized treatment of solid tumors, particularly gastrointestinal tumors. He is a key member of the multidisciplinary team for gastrointestinal cancer at Peking Union Medical College Hospital.
Associate Chief Physician, Associate Professor
Core Indications & Conditions Treated
Dr. Shao Yajuan is an Associate Chief Physician and Associate Professor in Medical Oncology, primarily engaged in the treatment of lung cancer and molecular targeted therapies.
Associate Chief Physician, Associate Professor
Core Indications & Conditions Treated
Dr. Jia Ning is an Associate Chief Physician and Associate Professor in Medical Oncology, focusing on head and neck neoplasms and chemotherapy research.
Chief Physician, Professor
Core Indications & Conditions Treated
Dr. Ba Yi is a Chief Physician and Professor in Medical Oncology, specializing in the diagnosis and treatment of gastrointestinal tumors and immunotherapy.
Associate Chief Physician
Core Indications & Conditions Treated
Dr. Cheng Yuejuan is an Associate Chief Physician in Medical Oncology, focusing on the medical treatment of pancreatic cancer and neuroendocrine tumors.
Chief Physician, Professor
Core Indications & Conditions Treated
Dr. Bai Chunmei is a Chief Physician and Professor specializing in gastrointestinal tumors and personalized treatment of neuroendocrine tumors.
Chief Physician, Associate Professor
Core Indications & Conditions Treated
Dr. Zhao Lin is a Chief Physician and Associate Professor specializing in chemotherapy and comprehensive treatment of tumors, particularly gastrointestinal tumors.
Associate Chief Physician, Associate Professor
Core Indications & Conditions Treated
Dr. Ying Hongyan is an Associate Chief Physician and Associate Professor specializing in breast cancer, neuroendocrine tumors, and comprehensive treatment of gastrointestinal tumors.
Chief Physician, Professor
Core Indications & Conditions Treated
Dr. Wang Yingyi is a Chief Physician and Professor with expertise in precision diagnosis and targeted therapy for lung cancer, as well as immunotherapy and personalized treatment strategies.
Associate Chief Physician, Lecturer
Core Indications & Conditions Treated
Dr. Li Ningning is an Associate Chief Physician in Medical Oncology, specializing in gastrointestinal cancers and their treatment, with significant experience in managing complex cases.
Attending Physician
Core Indications & Conditions Treated
Dr. Ge Yuping is an attending physician in medical oncology, specializing in gastrointestinal cancers. He has extensive experience in the comprehensive treatment of various malignancies.
Associate Chief Physician
Core Indications & Conditions Treated
Dr. Wang Xiang is an Associate Chief Physician in Medical Oncology, with expertise in the comprehensive treatment of gastrointestinal tumors, particularly pancreatic and gastric cancers, and managing elderly patients with multiple comorbidities.
Associate Chief Physician
Core Indications & Conditions Treated
Dr. Zhou Na is an Associate Chief Physician in Medical Oncology, specializing in the comprehensive treatment of malignant tumors of the esophagus and esophagogastric junction, with a focus on targeted therapy and immunotherapy.
Attending Physician
Core Indications & Conditions Treated
Dr. Zhang Zhiyang is an attending physician in medical oncology, with expertise in colorectal, gastric, pancreatic, liver, and biliary system tumors.
Attending Physician
Core Indications & Conditions Treated
Dr. Gong Xiaolei is an Attending Physician in the Department of Medical Oncology, specializing in the comprehensive treatment of gastric, colorectal, pancreatic, and esophageal cancers.
Resident Physician
Core Indications & Conditions Treated
Dr. Gu Junjie is a resident physician in medical oncology, focusing on the diagnosis and treatment of common internal medicine diseases. He has extensive clinical experience in managing various conditions.
Attending Physician
Core Indications & Conditions Treated
Dr. Liu Yuan is an attending physician in the Medical Oncology Department at Peking Union Medical College Hospital, experienced in the diagnosis and treatment of various solid tumors.
Attending Physician
Core Indications & Conditions Treated
Dr. Geng Ruixuan is an attending physician in the Department of Medical Oncology, specializing in pharmacological treatment of malignant solid tumors, targeted therapy, and immunotherapy.
Attending Physician
Core Indications & Conditions Treated
Dr. Liu Lian is an attending physician specializing in comprehensive treatment of gastrointestinal tumors, including targeted therapy for BRAF V600E mutant colorectal cancer.
Attending Physician
Core Indications & Conditions Treated
Dr. Yao Guangyu is an attending physician in medical oncology, specializing in the comprehensive treatment of esophageal, gastric, colorectal, and pancreatic cancers. He emphasizes patient management, communication, and follow-up on adverse reactions, and has participated in multiple clinical drug studies.
Independent support for patients seeking care at PUMCH
Century-Old Heritage · Premier Specialties
